Biolamina Is A Swedish Biotechnology Company Founded In 2008 By Drkarl Tryggvason And Drkristian Tryggvasonthe Company Specializes In Developing Advanced Cell Culture Solutions That Support Stem Cell Researchdrug Developmentand Cell Therapy Applicationsheadquartered In Swedenbiolamina Focuses On Biologically Relevant Substrates To Facilitate The Transition From Scientific Discovery To Clinical Implementation The Company S Flagship Products Are Biolamininasubstrateswhich Are Made From Full Lengthhuman Recombinant Laminin Proteinsthese Substrates Are Essential For Culturing Sensitive Cell Typesincluding Embryonic Stem Cellsinduced Pluripotent Stem Cellsand Primary Cells Like Neurons And Cardiomyocytesbiolamina S Solutions Enable Efficientstandardizedand Xeno Free Cell Culture Systemsaddressing Key Challenges In Maintaining Cell Quality And Functionality Biolamina Collaborates With Various Sectorsincluding Academia And Pharmaceuticalsand Has Partnered With Novo Nordisk To Develop Cell Therapies For Conditions Such As Parkinsonae S Disease And Heart Failurewith A Commitment To Scientific Rigor And Customer Centric Innovationbiolamina Aims To Be A Leading Provider Of Primary Cell Culture Solutions That Contribute To Life Saving Therapies
